NCT03302091

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

Pharmacokinetics, Safety and Tolerability After Multiple Dose Administration of BI 1467335 in Subjects With Moderate Renal Impairment and Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Accepted

Summary

The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.

Conditions

• Renal Insufficiency
• Healthy

Interventions

Type	Name	Description
DRUG	BI 1467335	28 day treatment period

Timeline

• Start date: 2017-10-17
• Primary completion: 2018-08-16
• Completion: 2018-08-16
• First posted: 2017-10-04
• Last updated: 2021-06-04
• Results posted: 2021-06-04

Locations

1 site across 1 country: Germany